EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

Chukiat Sirivichayakul, Shibadas Biswal, Xavier Saez-Llorens, Eduardo López-Medina, Charissa Borja-Tabora, Lulu Bravo, Pope Kosalaraksa, Maria Theresa Alera, Humberto Reynales, Luis Rivera, Veerachai Watanaveeradej, Delia Yu und 22 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae222 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Chukiat Sirivichayakul und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Yellow Fever Vaccine, Japanese Encephalitis Vaccines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003.

Methods

Children 4–16 years of age were randomized 2:1 to receive TAK-003 or placebo and were under active febrile surveillance. Symptomatic dengue was confirmed by serotype-specific reverse-transcription polymerase chain reaction. YF and JE vaccination history was recorded.

Results

Of the 20 071 children who received TAK-003 or placebo, 21.1% had a YF and 23.9% had a JE vaccination history at randomization. Fifty-seven months after vaccination, vaccine efficacy (95% confidence interval) was 55.7% (39.7%–67.5%) in those with YF vaccination, 77.8% (70.8%–83.1%) for JE vaccination, and 53.5% (45.4%–60.4%) for no prior YF/JE vaccination. Regional differences in serotype distribution confound these results. The apparent higher vaccine efficacy in the JE vaccination subgroup could be largely explained by serotype-specific efficacy of TAK-003. Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups.

Conclusions

The available data do not suggest a clinically relevant impact of prior JE or YF vaccination on TAK-003 performance. Overall, TAK-003 was well-tolerated and efficacious in different epidemiological settings. Clinical Trials Registration. NCT02747927.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VaccinesDengueYellow Fever VaccineJapanese Encephalitis VaccinesEncephalitis, JapaneseHumansChildFemaleMaleChild, PreschoolAdolescentVaccinationVaccine EfficacyYellow FeverDengue Virus

Stichwörter der Autor:innen

Japanese encephalitisTAK-003 effectivenessdenguevaccinationyellow fever

Substanzen

Dengue VaccinesYellow Fever VaccineJapanese Encephalitis Vaccines

Autor:innen und Institutionen

  • Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Takeda Vaccines, Inc., Cambridge, Massachusetts, USA.
  • Pediatric Infectious Diseases, Hospital del Niño Dr José Renán Esquivel, Sistema Nacional de Investigación at SENACYT, Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • Centro de Estudios en Infectologia Pediátrica, Universidad del Valle and Clínica Imbanaco Grupo Quironsalud, Cali, Colombia.
  • Clinical Research Division, Research Institute for Tropical Medicine, Muntinlupa, Philippines.
  • Pediatrics, University of the Philippines Manila, Ermita, Philippines.

ORCID-Profile: Vianney Tricou

Förderung

  • Takeda

Zitieren

APA

Sirivichayakul, C., Biswal, S., Saez-Llorens, X., López-Medina, E., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Alera, M. T., Reynales, H., Rivera, L., Watanaveeradej, V., Yu, D., Espinoza, F., Dietze, R., Fernando, L., Wickramasinghe, V. P., Moreira, E. D., Fernando, A. D., Gunasekera, D., …, & TIDES Study Group (2024). Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae222

Vancouver

Sirivichayakul C, Biswal S, Saez-Llorens X, López-Medina E, Borja-Tabora C, Bravo L, et al. Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae222

BibTeX
@article{Sirivichayakul2024,
  author = {Sirivichayakul, Chukiat and Biswal, Shibadas and Saez-Llorens, Xavier and López-Medina, Eduardo and Borja-Tabora, Charissa and Bravo, Lulu and Kosalaraksa, Pope and Alera, Maria Theresa and Reynales, Humberto and Rivera, Luis and Watanaveeradej, Veerachai and Yu, Delia and Espinoza, Felix and Dietze, Reynaldo and Fernando, LakKumar and Wickramasinghe, V Pujitha and Moreira, Edson Duarte and Fernando, Asvini D and Gunasekera, Dulanie and Luz, Kleber and Venâncio da Cunha, Rivaldo and Oliveira, Ana Lucia and Rauscher, Martina and Fan, Huihao and Borkowski, Astrid and Escudero, Ian and Tuboi, Suely and Lloyd, Eric and Tricou, Vianney and Folschweiller, Nicolas and LeFevre, Inge and Vargas, Luis Martinez and Wallace, Derek and TIDES Study Group, TIDES Study Group},
  title = {Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae222}
}
Kostenlos starten →